BACKGROUND: Premature ejaculation (PE) is a very common sexual dysfunction among patients, and with varying prevalence estimates ranging from 3% to 20%. Although psychological issues are present in most patients with premature PE, as a cause or as a consequence, research on the effects of psychological approaches for PE has in general not been controlled or randomised and is lacking in long-term follow up. OBJECTIVE: To assess the efficacy of psychosocial interventions for PE.

Background Tinnitus is the perception of sound without external acoustic stimuli. Patients with severe tinnitus may have physical and psychological complaints and their tinnitus can cause deterioration in their quality of life. At present no specific therapy for tinnitus has been found to be satisfactory in all patients. In recent decades, a number of reports have suggested that oral zinc supplementation may be effective in the management of tinnitus. Since zinc has a role in cochlear physiology and in the synapses of the auditory system, there is a plausible mechanism of action for this treatment. Objectives To evaluate the effectiveness and safety of oral zinc supplementation in the management of patients with tinnitus.

Background Vitamin D deficiency has been linked to the increased severity of numerous viral infections. Objective To assess whether vitamin D supplementation is safe and effective for the treatment of COVID‐19. Methods We searched MEDLINE, EMBASE, CENTRAL, LILACS and LOVE for randomised controlled trials (RCTs) published up to 2 March evaluating the effects of vitamin D for the treatment of coronavirus disease (COVID‐19). Two authors selected the studies and analysed the data evidence following Cochrane Recommendations. Results We included three RCTs with a total of 385 participants. We found low certainty evidence indicating that hospitalised patients under calcifediol plus standard care (SC) treatment seem to present a significantly lower risk of being admitted to ICU but no difference in mortality. We found low to very low certainty evidence that the improvement in fibrinogen levels is slightly greater in mildly symptomatic or asymptomatic patients with COVID‐19 that used cholecalciferol plus SC than in those treated with placebo plus SC (mean difference), and the patients who used cholecalciferol plus SC achieved more SARS‐CoV‐2 negativity, but not on d‐dimer, c‐reactive protein (CRP) or procalcitonin compared with the patients in the placebo plus SC group. We also found low to moderate certainty evidence that a single high dose of vitamin D does not seem to be effective for reducing mortality, length of hospital stay, ICU admissions and d‐dimer or CRP levels when used in patients with moderate to severe COVID‐19. Conclusions As a practical implication, the use of vitamin D associated with SC seems to provide some benefit to patients with COVID‐19. However, the evidence is currently insufficient to support the routine use of vitamin D for the management of COVID‐19, as its effectiveness seems to depend on the dosage, on the baseline vitamin D levels, and on the degree of COVID‐19 severity.

Pre-SA increases the chance of biochemical control of acromegaly 3 months after TSS in patients harboring GH-secreting pituitary macroadenomas.